Intec Pharma Ltd., of Jerusalem, said the underwriters of its previously announced IPO in the U.S. have exercised in part their overallotment option and purchased an additional 638,750 ordinary shares at the IPO price of $6 per ordinary share resulting in additional gross proceeds to the company of approximately $3.8 million. Read More
Infinity Pharmaceuticals Inc., of Cambridge, Mass., said it expanded its pipeline with the addition of IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), for the treatment of solid tumors. Read More
Aquinox Pharmaceuticals Inc., of Vancouver, British Columbia, said it presented additional exploratory analyses of responder rates for average daily pain and maximum daily pain from its LEADERSHIP phase II trial in patients with bladder pain syndrome/interstitial cystitis (BPS/IC) at the International Society for the Study of BPS (ESSIC) conference in Rome. Read More
A team from the University of California at Berkeley, the Salk Institute for Biological Studies and the European Molecular Biology Laboratory has shown that aging is not a unified process, but instead affects different organs in different ways. Read More
LONDON – The EMA has opened a public consultation on the use of digital sensors embedded within pills to measure adherence and physiologic response, after concluding this form of tracking should be given its seal of approval as a biomarker in clinical trials. Read More
LONDON – The UK's Human Embryology and Fertilization Authority (HFEA) has received the first application for a license to use the precise genome editing tool CRISPR/Cas9 in human embryo research. Read More
SAN DIEGO – Enterococci, or at least their consequences, were on the public's mind in the runup to the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting. Read More
BOSTON – As attendees headed home from Biopharm America, likely one of the better-recalled sessions was the pharma roundtable that provided a packed room with glimpses inside some of the major deal makers and how they operate. Read More
Among the great hopes of 21st century medical science is that the Precision Medicine Initiative (PMI) will help doctors and patients avoid ineffective treatment regimes. A government panel recently published a report on the million-person cohort needed to make the PMI program a reality. Read More
Shares of Tracon Pharmaceuticals Inc. (NASDAQ:TCON) soared 36 percent Friday after the company reported a complete response (CR) in a single-patient compassionate use phase II study of its anticancer candidate, TRC105, in the rare indication of choriocarcinoma, an aggressive form of gestational trophoblastic neoplasia (GTN). Read More
